TY - JOUR
T1 - The broader impacts of otitis media and sequelae for informing economic evaluations of pneumococcal conjugate vaccines
AU - Perdrizet, Johnna
AU - Farkouh, Raymond A.
AU - Horn, Emily K.
AU - Hayford, Kyla
AU - Sings, Heather L.
AU - Wasserman, Matt D.
N1 - Funding Information:
Medical writing was provided by Dr. Jonathan Pitt (Evidera, Paris, France) and funded by Pfizer Inc.
Publisher Copyright:
© 2022 Pfizer Inc. Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Introduction: Otitis media (OM) is a common childhood infection. Pneumococcal conjugate vaccines (PCVs) prevent OM episodes, thereby reducing short- and long-term clinical, economic, humanistic, and societal consequences. Most economic evaluations of PCVs focus on direct health gains and cost savings from prevented acute episodes but do not fully account for the broader societal impacts of OM prevention. Areas covered: This review explores the broader burden of OM on children, caregivers, and society to better inform future economic evaluations of PCVs. Expert opinion: OM causes a substantial burden to society through long-term sequelae, productivity losses, reduced quality of life for children and caregivers, and contribution to antimicrobial resistance from inappropriate antibiotic use. The effect of PCVs on acute OM has been recognized globally, yet the broader impact has not been consistently quantified, studied, or communicated. Economic evaluations of PCVs must evolve to include broader effects for patients, caregivers, and society from OM prevention. Future PCVs with broader coverage may further reduce OM incidence and antimicrobial resistance, but optimal uptake will depend on increasing the recognition and use of novel frameworks that include broader benefits. Communicating the full value of PCVs to decision makers may result in wider access and positive societal returns.
AB - Introduction: Otitis media (OM) is a common childhood infection. Pneumococcal conjugate vaccines (PCVs) prevent OM episodes, thereby reducing short- and long-term clinical, economic, humanistic, and societal consequences. Most economic evaluations of PCVs focus on direct health gains and cost savings from prevented acute episodes but do not fully account for the broader societal impacts of OM prevention. Areas covered: This review explores the broader burden of OM on children, caregivers, and society to better inform future economic evaluations of PCVs. Expert opinion: OM causes a substantial burden to society through long-term sequelae, productivity losses, reduced quality of life for children and caregivers, and contribution to antimicrobial resistance from inappropriate antibiotic use. The effect of PCVs on acute OM has been recognized globally, yet the broader impact has not been consistently quantified, studied, or communicated. Economic evaluations of PCVs must evolve to include broader effects for patients, caregivers, and society from OM prevention. Future PCVs with broader coverage may further reduce OM incidence and antimicrobial resistance, but optimal uptake will depend on increasing the recognition and use of novel frameworks that include broader benefits. Communicating the full value of PCVs to decision makers may result in wider access and positive societal returns.
KW - Burden of disease
KW - clinical and social burden
KW - cost-effectiveness analysis
KW - economic evaluation
KW - healthcare costs
KW - hearing loss
KW - otitis media
KW - pneumococcal conjugate vaccines
KW - quality of life
KW - socioeconomic benefits
UR - http://www.scopus.com/inward/record.url?scp=85125390286&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125390286&partnerID=8YFLogxK
U2 - 10.1080/14760584.2022.2040989
DO - 10.1080/14760584.2022.2040989
M3 - Review article
C2 - 35191368
AN - SCOPUS:85125390286
SN - 1476-0584
VL - 21
SP - 499
EP - 511
JO - Expert Review of Vaccines
JF - Expert Review of Vaccines
IS - 4
ER -